Biomarkers for physical frailty and sarcopenia: state of the science and future developments.
Biomarkers for physical frailty and sarcopenia: state of the science and future developments.
复制标题
DOI：
10.1002/jcsm.12051
复制
发表时间：
2015-12
期刊：
影响因子：
--
通讯作者：
SPRINTT consortium
中科院分区：
文献类型：
--
作者：
Calvani R;Marini F;Cesari M;Tosato M;Anker SD;von Haehling S;Miller RR;Bernabei R;Landi F;Marzetti E;SPRINTT consortium
身体虚弱和肌肉减少症是两种常见的，在很大程度上重叠的老年疾病上游的残疾级联。身体虚弱和肌肉减少症缺乏独特的操作定义以及复杂的潜在病理生理学使得这些疾病的生物标志物的开发极具挑战性。事实上，目前的定义模糊的身体虚弱和肌肉减少症，连同其异质性的临床表现，影响的准确性，特异性和灵敏度的个人生物标志物提出了迄今为止。在这篇综述中，目前的最新技术水平的发展生物标志物的身体虚弱和肌肉减少症。还介绍了一种新的生物标志物鉴定和验证方法，从“一个适合所有”的范式移动到多变量方法。
Physical frailty and sarcopenia are two common and largely overlapping geriatric conditions upstream of the disabling cascade. The lack of a unique operational definition for physical frailty and sarcopenia and the complex underlying pathophysiology make the development of biomarkers for these conditions extremely challenging. Indeed, the current definitional ambiguities of physical frailty and sarcopenia, together with their heterogeneous clinical manifestations, impact the accuracy, specificity, and sensitivity of individual biomarkers proposed so far. In this review, the current state of the art in the development of biomarkers for physical frailty and sarcopenia is presented. A novel approach for biomarker identification and validation is also introduced that moves from the ‘one fits all’ paradigm to a multivariate methodology.